September 30, 2024 09:00 AM EDT
Startups
R&D

Rivus de­tails weight loss da­ta in heart fail­ure pa­tients and preps for new fundraise

Max Bayer

Pharma Reporter

Rivus Phar­ma­ceu­ti­cals’ obe­si­ty treat­ment for pa­tients with heart fail­ure spurred a 6.3-pound drop in weight com­pared to place­bo af­ter three months of treat­ment, said the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Cal­i­for­ni­a's Gavin New­som ve­toes bi­par­ti­san PBM re­form bill

J&J pulls the plug on 340B re­bate mod­el changes op­posed by gov­ern­ment

Po­sei­da shares in­cre­men­tal Phase 1 up­date for Roche-part­nered off-the-shelf CAR-T

Up­dat­ed: Roche buys Re­gor’s CDK in­hibitors for $850M up­front amid push to de­vel­op 20 ‘trans­for­ma­tive’ med­i­cines

Up­dat­ed: Prime Med­i­cine whit­tles down pipeline, signs gene edit­ing deal with Bris­tol My­ers

sponsored

3 Tiers for AAV Po­ten­cy As­say De­vel­op­ment Suc­cess

A service from the Financial Times